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Abstract
Background: We sought to examine whether ε4 carrier status modifies the relation between body mass index
(BMI) and HDL. The National Heart, Lung, and Blood Institute Family Heart Study included 657 families with high
family risk scores for coronary heart disease and 588 randomly selected families of probands in the Framingham,
Atherosclerosis Risk in Communities, and Utah Family Health Tree studies. We selected 1402 subjects who had ε4
carrier status available. We used generalized estimating equations to examine the interaction between BMI and ε4
allele carrier status on HDL after adjusting for age, gender, smoking, alcohol intake, mono- and poly-unsaturated fat
intake, exercise, comorbidities, LDL, and family cluster.
Results: The mean (standard deviation) age of included subjects was 56.4(11.0) years and 47% were male. Adjusted
means of HDL for normal, overweight, and obese BMI categories were 51.2(± 0.97), 45.0(± 0.75), and 41.6(± 0.93),
respectively, among 397 ε4 carriers (p for trend < 0.0001) and 53.6(± 0.62), 51.3(± 0.49), and 45.0(± 0.62),
respectively, among 1005 non-carriers of the ε4 allele (p-value for trend < 0.0001). There was no evidence for an
interaction between BMI and ε4 status on HDL(p-value 0.39).
Conclusion: Our findings do not support an interaction between ε4 allele status and BMI on HDL.
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Introduction
HDL cholesterol (HDL) has been associated with lower
risk of coronary heart disease (CHD) in observational
and trial cohorts [1-8]. Apolipoprotein E (APOE) is a
protein component of triglyceride-rich lipoproteins and
thus participates in the transport of lipids among various
cells in the body [9]. There are 3 major isoforms of apoli-
poprotein E in modern populations, encoded by alleles
ε2, ε3, and ε4. The ε4 allele has been associated with
lower levels of HDL and higher risk of CHD events [10].
Higher body mass index (BMI) has also been found to be
associated with lower HDL levels and increased risk of
CHD [11-13]. In studies including subjects at average
risk for CHD, previous researchers have not found that a
BMI-genotype interaction impacts HDL levels [14-16].
However, to the best of our knowledge, no researchers
have reported whether APOE ε4 allele carrier status
modifies the relation between higher BMI and lower
HDL levels in a cohort enriched with subjects and
higher-than-average risk for CHD. This question may be
important from a clinical standpoint, to determine
whether carriers of Apo ε4 are at any disadvantage when
attempting to lower their BMI to achieve a more favor-
able lipid profile. Therefore, to evaluate whether there is
a significant interaction between BMI and APOE ε4 car-
rier status on HDL levels, we examined the relationship
between these in a cohort of 1402 men and women
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selected from the National Heart, Lung, and Blood Insti-
tute Family Heart Study (NHLBI FHS).
Methods
Population
The NHLBI FHS is a multicenter, population-based study
that includes probands recruited from three parent stu-
dies: the Framingham Heart Study (Framingham, MA),
the Atherosclerosis Risk in Communities Study (Forsythe
County, NC and Minneapolis, MN), and the Utah Family
Health Tree (Salt Lake City, UT). Between 1993 and
1995, 2,000 randomly selected participants and 2,000
with family histories of CHD enrolled in the 3 parent stu-
dies were mailed invitations to provide information
regarding the health of themselves, their parents, their
children, and their siblings. Of these, 3,150 returned
responses, and family members of these responders were
contacted. From the 22,908 persons who provided infor-
mation, 588 families were randomly selected and an addi-
tional 657 with high family risk scores were also selected.
Family risk score was calculated by comparing the actual
incidence of CHD to the age- and sex-adjusted expected
incidence of CHD within a family. Enrollees underwent
study examinations during which height, weight and
blood pressure were documented, and 12-hour fasting
blood samples were taken on which lipids and other
parameters were measured, and from which DNA was
stored. Genotyping for the APOE allele was performed
on a selection of FHS participants. More detailed descrip-
tion of the methods of the NHLBI FHS have been
described previously [17]. The FHS is supported by the
National Heart, Lung, and Blood Institute (NHLBI)
(grant numbers U01 HL56563, U01 HL56564, U01
HL56565, U01 HL56566, U01 HL56567, U01 HL56568,
U01 HL56569, and K01-HL70444). Each participant in
the FHS gave informed consent and the study protocol
was reviewed and approved by the respective Internal
Review Boards at each of the participating institutions.
For this study, we selected subjects with information on
APOE genotype and with complete data on lipids, life-
style factors, and co-morbidities. Due to small numbers
of non-white subjects, participants of other races (54 sub-
jects) were excluded from this study, as were 34 subjects
who were using cholesterol modifying therapy. Finally 37
subjects were excluded with the ε2/ε4 genotype, as the ε2
allele has been associated with higher levels of HDL
while ε4 carrier status has been associated with lower
HDL levels [18].
Exposure
APOE genotyping was performed using polymerase
chain reaction (PCR) to amplify a 267-base pair frag-
ment from exon 3 of the APOE gene. The PCR product
was digested using the Hha-1 restriction endonuclease,
which resulted in a specific banding pattern for the 3
isoforms of the apolipoprotein E protein when separated
by polyacrylamide gel electrophoresis and silver stained
[19]. Subjects with genotypes of ε3/ε4 or ε4/ε4 were car-
riers; subjects with genotypes of ε2/ε2, ε2/ε3, or ε3/ε3
were non-carriers.
Height and weight documented during the study exami-
nation were used to calculate body mass index (BMI).
BMI was treated both as a continuous and a categorized
variable (BMI < 25 kg/m2, 25 ≤ BMI < 30 kg/m2, and BMI
≥ 30 kg/m2) in the analyses described below.
Lipid measurements
During the study visits, a fasting blood sample was col-
lected in evacuated tubes without additives, spun at
3000xg for 10 minutes at 4°C, and stored at -70° until they
were processed. HDL, total cholesterol, and triglyceride
concentrations were measured using a COBAS FARA
high-speed centrifugal analyzer (Roche Diagnostic Sys-
tems, Montclair, New Jersey).
Covariates
Information on lifestyle factors including smoking (cur-
rently smoking versus not currently smoking), alcohol
intake (consumption of 2 or more beverages daily), and
physical activity (minutes of exercise per day) was
obtained by interview during the study visit. Mono- and
poly-unsaturated fat intake (MUFA and PUFA, in grams)
was determined using a previously validated food fre-
quency questionnaire administered by study staff during
the study interview and a nutrient database from Harvard
University supplemented by manufacturer’s information
[20]. Participants provided self-reported information on
co-morbities including angina, CHD, stroke, cancers, and
hypertension. A subject was deemed to have diabetes
mellitus if he was taking hypoglycemic agents, if a physi-
cian had told the subject that he had diabetes mellitus, or
if fasting blood glucose was ≥ 126 mg/dL. In subjects
with triglycerides < 400 mg/dL, LDL (LDL) was calcu-
lated using measured HDL, total cholesterol, and trigly-
cerides. LDL was measured directly on EDTA plasma
using ultracentrifugation on EDTA plasma in subjects
with triglycerides ≥ 400 mg/dL.
Statistical Analyses
The chi-square test was used to determine whether the
APOE allele distribution was in Hardy-Weinberg equili-
brium in this population prior to exclusions. We com-
pared characteristics of the cohort by ε4 carrier status and
by BMI category, using t-tests to compare continuous
variables and Cochran-Mantel-Haenszel tests to compare
categorical variables. We then used generalized estimating
equations (GEE, using the LSMEANS option in PROC
GENMOD in SAS) to determine adjusted means and
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standard errors for HDL across BMI categories, in
subgroups by ε4 carrier status. GEE adjusts for familial
clustering in the NHLBI FHS. Means were adjusted for
age, categorized BMI, gender, current smoking status,
alcohol consumption (≥ 2 beverages daily versus non or <
2 daily), minutes of exercise daily, mono- and PUFA intake
in grams, angina, stroke, hypertension, coronary heart dis-
ease, diabetes mellitus, and LDL. We determined the para-
meter estimate and p-value for a categorized BMIxε4
carrier product term in a model including the main effects
of categorized BMI and carrier status, plus age, gender,
lifestyle factors, co-morbidities, and LDL. In secondary
analyses, we examined whether a continuous BMIxε4 car-
rier product term was significantly associated with HDL
after adjusting for the main effects of continuous BMI and
carrier status and age, then additionally adjusting for gen-
der, lifestyle factors, co-morbidities, and LDL. We did not
include triglycerides in adjusted models due to collinearity
between the outcome (HDL) and triglycerides as pre-
viously modeled by others [21].
In a sensitivity analysis, we examined whether there
was a significant association between continuous BMIxε4
carrier product term and HDL in a sub-cohort consisting
of one individual (randomly selected) per family, and in
subgroups of participants defined by CHD risk (members
of randomly selected families versus members of families
with increased CHD risk). To examine whether there was
a significant interaction between BMI and APOE geno-
type (in contrast to carrier status for the ε4 allele) we
treated genotype as an ordinal variable (ε2/ε2, ε2/ε3, ε3/
ε3, ε3/ε4, ε4/ε4) and included a continuous BMIxgen-
otype product term in the model. To examine whether a
BMIxε4 carrier status interaction was significantly asso-
ciated with HDL in subgroups by gender, we repeated
the analysis including the main effects of BMI and ε4 car-
rier status and their interaction term in subgroups of
men and women. All analyses were performed using SAS
version 9.2 (SAS Institute Incorporated, Cary, North
Carolina).
Results
A total of 1402 NHLBI FHS participants from 662
families were included in our study. Each family contrib-
uted an average of 2 participants to our cohort (range, 1-
11 family members). The mean (standard deviation, SD)
age of the study cohort was 56.4 (11.0) years, 47% were
male, and about 75% had a BMI within the overweight or
obese range (≥ 25 kg/m2). As expected given the selection
method for the study, there was a high prevalence of
smoking (13%), angina (14%), CHD (18%), and hyperten-
sion (34%). The distribution of the APOE alleles was in
Hardy-Weinberg equilibrium (p-value 0.91). Overall, 28%
of subjects were carriers of the APOE ε4 allele. Table 1
presents characteristics of the cohort by ε4 carrier status.
The mean HDL among ε4 carriers was significantly lower
and the mean triglycerides significantly higher than those
among non-carriers. Carriers of the ε4 allele were
younger and more likely than non-carriers to be hyper-
tensive. Table 2 presents characteristics of the cohort
according to BMI category. Subjects with higher BMI
Table 1 Characteristics of n = 1402 National Heart, Lung, and Blood, Institute Family Heart Study participants, by
apolipoprotein ε4 carrier status.
Carriers of ε4 Non-carriers of ε4 p-value
Characteristic n = 397 (28.3%) n = 1005 (71.7%)
Age, mean (SD)* 54.9(10.9) 57.0(11.0) 0.001
Male, no. (%)* 193(48.6) 472(47.0) 0.58
BMI, kg/m2, mean (SD)* 28.3(5.3) 28.4(5.6) 0.89
Current smoker, no. (%) 45(11.3) 138(13.7) 0.23
≥ 2 alcoholic drinks daily, no. (%) 197(49.6) 497 (49.5) 0.95
Monounsaturated fat intake, g/day, mean (SD) 24.7(13.9) 23.3(12.5) 0.06
Polyunsaturated fat intake, g/day, mean (SD) 9.1(5.1) 8.7(4.6) 0.17
Exercise in minutes/day, mean (SD) 26.8(37.3) 28.2(34.7) 0.51
HDL, mg/dL, mean (SD)* 45.8(14.1) 49.1(15.8) 0.0003
LDL, mg/dL, mean (SD) 132.8(37.0) 128.8(35.5) 0.06
Triglycerides, mg/dL, mean (SD) 178.7(102.0) 164.4(109.3) 0.03
Diabetes mellitus, no. (%) 27(6.8) 95(9.5) 0.11
Hypertension, no. (%) 116(29.2) 364(36.2) 0.01
Coronary heart disease, no. (%) 72(18.1) 176(17.5) 0.78
Angina, no. (%) 46(11.6) 150(14.9) 0.10
Stroke, no. (%) 13(3.3) 35(3.5) 0.85
Cancer, no. (%) 45(11.3) 111(11.0) 0.88
*BMI = Body Mass Index; HDL = high-density lipoprotein cholesterol; kg/m2 = kilograms/meters-squared; LDL = low-density lipoprotein cholesterol; mg/dL =
milligrams/deciliter; No. = number; SD = standard deviation
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were more likely to be male, have a higher fat intake,
exercised for fewer minutes daily, had lower HDL,
and were more likely to have diabetes mellitus or
hypertension.
Table 3 presents multivariate adjusted means ± stan-
dard errors of HDL in each BMI category, in subgroups
by ε4 carrier status. As BMI increases, HDL decreases in
both ε4 carriers and non-carriers (p-value for trend <
0.0001 in each subgroup). In an analysis including the
main effects of categorized BMI and ε4 carrier status,
there was no significant association between a categor-
ized BMIxε4 carrier product term and HDL (p-value
0.75, results not shown). Table 3 also presents the para-
meter estimates and p-values for BMI as a continuous
Table 2 Characteristics of the n = 1402 participants, by category of body mass index.
BMI ≤ 25 kg/m2* 25 < BMI ≤ 30 kg/m2 BMI > 30 kg/m2
Characteristic n = 407 (29.0%) n = 565 (40.3%) n = 430 (30.7%) p-value
Age, mean (SD)* 56.2 (11.1) 57.1 (11.3) 55.8 (10.6) 0.57
Carrier ε4 allele, no. (%)* 112 (27.5) 162 (28.7) 123 (28.6) 0.73
Male, no. (%) 143 (35.1) 330 (58.4) 192 (44.7) 0.008
BMI, kg/m2, mean (SD)* 22.8 (1.7) 27.4 (1.4) 34.9 (4.6) –
Current smoker, no. (%) 69 (17.0) 77 (13.6) 37 (8.6) 0.0003
≥ 2 alcoholic drinks daily, no. (%) 209 (51.4) 287 (50.8) 198 (46.1) 0.12
Monounsaturated fat intake, mean (SD) 21.8 (12.6) 24.0 (12.5) 25.0 (37.0) 0.0004
Polyunsaturated fat intake, mean (SD) 8.4 (4.4) 8.9 (4.7) 9.2 (5.1) 0.02
Exercise in minutes/day, mean (SD) 30.1 (33.8) 28.6 (35.3) 24.5 (37.0) 0.02
HDL, mg/dL, mean (SD)* 55.1 (17.5) 46.5 (14.2) 44.0 (12.4) < 0.0001
LDL, mg/dL, mean (SD)* 129.7 (35.1) 131.5 (38.9) 128.2 (32.5) 0.53
Triglycerides, mg/dL, mean (SD) 134.0 (105.7) 179.5 (103.0) 186.6 (107.5) < 0.0001
Diabetes mellitus, no. (%) 17 (4.2) 53 (9.4) 52 (12.1) < 0.0001
Hypertension, no. (%) 103 (25.3) 202 (35.8) 175 (40.7) < 0.0001
Coronary heart disease, no. (%) 57 (14.0) 127 (22.5) 64 (14.9) 0.79
Angina, no. (%) 36 (8.9) 107 (18.9) 53 (12.3) 0.17
Stroke, no. (%) 9 (2.2) 28 (5.0) 11 (2.6) 0.82
Cancer, no. (%) 38 (9.3) 73 (12.9) 45 (10.5) 0.63
*BMI = Body Mass Index; HDL = high-density lipoprotein cholesterol; kg/m2 = kilograms/meters-squared; LDL = low-density lipoprotein cholesterol; mg/dL =
milligrams/deciliter; No. = number; SD = standard deviation
Table 3 Adjusted mean (± standard error, SE) high-density lipoprotein cholesterol in each category of body mass
index(BMI), by ε4 carrier status (top section) and parameter estimates ± SE and p-values for continuous BMI and
continuous BMI × ε4 carrier status (bottom section).
n ε4 Carriers n ε4 Non-carriers Overall cohort
HDLa, mg/dL, mean ± SE* Parameter estimate(SE) p-value
BMI ≤ 25 kg/m2* 112 51.2 ± 0.97 295 53.6 ± 0.62
25 < BMI ≤ 30 kg/m2 162 45.0 ± 0.75 403 51.3 ± 0.49
BMI ≥ 30 kg/m2 123 41.6 ± 0.93 307 45.0 ± 0.62
P-value for trend < 0.0001 < 0.0001
BMI
Adjusted for age and carrier status -0.69(0.07) < 0.0001
Adjusted for age, carrier status, and interaction -0.70(0.08) < 0.0001
Multivariate-adjustedb -0.75(0.07) < 0.0001
Continuous BMI × carrier term
Adjusted for age, BMI, and carrier status 0.02(0.14) 0.90
Multivariate-adjustedb 0.10(0.12) 0.39
*BMI = Body Mass Index; HDL = high-density lipoprotein cholesterol; mg/dL = milligrams/deciliter; kg/m2 = kilograms/meters-squared
┼Multivariate-adjusted estimates for HDL are adjusted for age, gender, categorized BMI, current smoker (yes/no), alcohol intake(≥ 2 beverages daily, yes/no),
monounsaturated fat intake in grams, polyunsaturated fat intake in grams, minutes of exercise daily, angina, coronary heart disease, stroke, cancer, hypertension,
diabetes mellitus, and low-density lipoprotein cholesterol
bMultivariate-adjusted parameter estimates are adjusted for age, gender, continuous BMI, ε4 carrier status, continuous BMIxε4 carrier interaction, current smoker
(yes/no), alcohol intake (≥ 2 beverages daily, yes/no), monounsaturated fat intake in grams, polyunsaturated fat intake in grams, minutes of exercise daily, angina,
coronary heart disease, stroke, cancer, hypertension, diabetes mellitus, and LDL.
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variable and for a continuous BMI × ε4 carrier product
term. The association between continuous BMI and HDL
remains robust, with or without adjustment for the BMI
× ε4 carrier product term and other co-variates including
gender, lifestyle factors, LDL, and co-morbidities. In age-
and multivariate-adjusted parameter estimates, there was
no significant association between the continuous BMI ×
ε4 carrier product term and HDL (multivariate parameter
estimate 0.11, p-value 0.39).
In a sensitivity analysis including one member per
family, results again revealed that after adjusting for the
main effects of BMI and ε4 carrier status, a continuous
BMI × carrier product term remained non-significant
(results not shown). Repeating the analysis in subgroups
consisting of participants from randomly selected families
versus those with increased CHD risk, we found that
results were similar (not shown). In an analysis treating
APOE genotype as an ordinal variable and including a
continuous BMI × genotype product term, the interaction
between genotype and BMI remained non -significant
(p-value for interaction 0.55; p-value for main effects of
continuous BMI and APOE genotype were 0.0008 and
0.24 respectively, when interaction term included in the
model, results not shown). In an analysis including the
main effects of continuous BMI and ε4 carrier status and a
continuous BMI × carrier product term in subgroups of
men and women, results were unchanged (results not
shown).
Discussion
In a cohort of 1402 men and women, we found that
APOE ε4 carrier status did not modify the strong associa-
tion between higher BMI and lower HDL levels. We
found that increasing BMI was significantly associated
with decreasing HDL, regardless of whether or not sub-
jects were carriers of the ε4 allele. These findings were
robust in subgroups by gender and in a cohort in which
only one member per family was included. In analyses
examining whether there was interaction between APOE
genotype and the BMI-HDL association, we again found
a strong association between increasing BMI and
decreasing HDL levels, regardless of genotype.
In subjects at average risk for CHD, previous researchers
have found that APOE genotype does not modify the asso-
ciation between measures of adiposity, including BMI and
waist-to-hip ratio, and HDL levels. In a Canadian cohort
including 1788 men and women of varying CHD risk, Lus-
sier-Cacan et al found that the relationship between BMI
and HDL did not vary significantly across APOE geno-
types [14]. We similarly found no difference in the relation
between BMI and HDL in ε4 carriers compared to non-
carriers. In a cohort of 759 young adults (aged 20 to 32
years) followed longitudinally, obese individuals had much
higher prevalence of low HDL levels compared to non-
obese individuals, but this did not differ across APOE gen-
otype categories [15]. Our study demonstrates that the
lack of modification of the BMI-HDL relation by ε4 carrier
status also extends to populations enriched with subjects
at higher risk for CHD.
APOE is synthesized by the liver as part of VLDL parti-
cles. In cholesterol transport, it serves as a ligand for sev-
eral processes that cycle triglycerides from VLDL into
HDL subtypes. The ε4 isoform of APOE is less effective in
binding to lipoprotein receptors than the ε2 or ε3 iso-
forms, so in individuals with APOE ε4 the pathway
between triglyceride-rich VLDL particles and small, den-
ser, more easily metabolized HDL particles is less effective
[9]. Though further research would be necessary to sup-
port any speculation regarding the metabolic pathway
between BMI, APOE, and HDL, our findings may suggest
that in the triglyceride-rich milieu associated with adipos-
ity, the effectiveness of the APOE as a ligand becomes
immaterial as the pathway between VLDL and HDL sub-
types is overwhelmed. In a supplemental analysis, we
examined whether an interaction between BMI and APOE
genotype impacted HDL levels and found no significant
association. This lends further support to the idea that the
effectiveness of one player, APOE, in the complex pathway
that metabolizes lipids becomes less important in the con-
text of high levels of substrate entering that pathway, as is
the case in subjects with high BMI.
There are several advantages to using the NHLBI FHS
database to examine whether there is a significant interac-
tion between BMI and ε4 carrier status in influencing
HDL levels, including detailed information on several life-
style factors that are associated with HDL (alcohol intake,
smoking, diet, and exercise). Misclassification of the main
exposure variable, namely BMI, is unlikely as height and
weight were determined by study staff during the study
visit. However there are some limitations to our study.
The small number of non-Caucasian subjects disallowed
us from examining whether there is a significant BMIx-
genotype association with HDL in persons of other racial
or ethnic groups. We may have been under-powered to
detect a small effect of a BMI × APOE interaction on
HDL levels. Confirming that no significant interaction
exists in larger cohorts remains an important area of
future research.
We found that ε4 carrier status does not modify the
well-established association between increasing BMI and
decreasing HDL levels. Our findings suggest that car-
riers of the ε4 allele who lower their BMI in an attempt
to improve their lipid profile may not be at a disadvan-
tage when compared to non-carriers of the allele. How-
ever, further study in larger cohorts and with subjects of
other races or ethnicity are warranted to definitively
establish whether ε4 carrier status modifies the BMI-
HDL association.
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